Named Patient Program for Olverembatinib (HQP1351)
Conditions Not listed
Trial statusAvailable
Trial phaseNot listed
Trial typeExpanded Access
Biological sexAll
Age18-99
SponsorAscentage Pharma Group Inc.
About this trial
This program will allow eligible patients access to Ascentage Pharma's novel drug candidate Olverembatinib (approved in China) on a named patient basis in over 100 countries ( with the exception of the USA and China) and regions where the drug is not available.
Eligibility criteria
Qualifiers
None
Disqualifiers
Existing risks of serious Arterial occlusive events (AOE), including myocardial infarction, stroke, stenosis of large arterial vessels of the brain, severe peripheral vascular disease, and recent revascularization procedures
Existing risks of serious Venous thromboembolic events (VTEs), including deep venous thrombosis, pulmonary embolism, and retinal vein thrombosis
Existing serious heart conditions, including acute/chronic heart failure, coronary artery disease
Existing conditions of severe liver malfunction
Trial design
Treatments tested in this trial
- Olverembatinib
Treatment groups
No treatment groups listed
Locations
Sponsors and collaborators
Ascentage Pharma Group Inc.
Lead sponsor
Tanner Pharma Group
Collaborator
Source ClinicalTrials.gov